Diagnostic approaches to acute promyelocytic leukaemia.
Delivering the most effective clinical therapy in acute promyelocytic leukaemia (APL) is dependent on accurately making the diagnosis. The morphological diagnosis can be improved by detecting the presence of a specific chromosome translocation, the t(15;17)(q22;q21). This can be achieved using cytogenetics, RT-PCR, FISH and anti-PML monoclonal antibody. The optimal approach will be rapid, accurate and readily integrated into the routine haematology laboratory. Immunofluorescent detection of microparticulate PML protein fulfils these criteria, however, karyotyping will also detect the variant translocations and remains the 'gold-standard'.
O'Connor
S J
SJ
Haematological Malignancy Diagnostic Service, The General Infirmary at Leeds, UK.
Evans
P A
PA
Morgan
G J
GJ
D002884:Chromosomes, Human, Pair 15; D002886:Chromosomes, Human, Pair 17; D003581:Cytodiagnosis; D005455:Fluorescent Antibody Technique; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D009363:Neoplasm Proteins / Q000235:genetics; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014178:Translocation, Genetic / Q000235:genetics
D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein